CLINICAL TRIALS PROFILE FOR FRUQUINTINIB
✉ Email this page to a colleague
All Clinical Trials for fruquintinib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01645215 ↗ | Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors | Completed | Fudan University | Phase 1 | 2011-01-01 | Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics , safety and preliminary anti-tumor activity of HMPL-013 at single doses and multiple doses . |
| NCT01645215 ↗ | Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors | Completed | Hutchison Medipharma Limited | Phase 1 | 2011-01-01 | Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics , safety and preliminary anti-tumor activity of HMPL-013 at single doses and multiple doses . |
| NCT01955304 ↗ | Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects | Completed | Hutchison Medipharma Limited | Phase 1 | 2012-06-01 | This study will determine the effect of food on the pharmacokinetics (PK) of a single dose of 4mg fruquintinib in normal healthy subjects. |
| NCT01975077 ↗ | A Phase Ib Study of Fruquintinib in 3rd Line mCRC | Completed | Fudan University | Phase 1/Phase 2 | 2012-12-01 | Fruquintinib is a novel oral small molecule compound discovered and developed by Hutchison MediPharma that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts.Based on first-in-human study, both 4mg QD and 5mg 3wks on/1wk off are safety and efficacy, this phase Ib study is to evaluable the safety, tolerability and efficacy of these 2 regimens with mCRC failed 2nd therapy or more and to determine the recommended dose and regimen in phase II/III study. |
| NCT01975077 ↗ | A Phase Ib Study of Fruquintinib in 3rd Line mCRC | Completed | Sun Yat-sen University | Phase 1/Phase 2 | 2012-12-01 | Fruquintinib is a novel oral small molecule compound discovered and developed by Hutchison MediPharma that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts.Based on first-in-human study, both 4mg QD and 5mg 3wks on/1wk off are safety and efficacy, this phase Ib study is to evaluable the safety, tolerability and efficacy of these 2 regimens with mCRC failed 2nd therapy or more and to determine the recommended dose and regimen in phase II/III study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for fruquintinib
Condition Name
Clinical Trial Locations for fruquintinib
Trials by Country
Clinical Trial Progress for fruquintinib
Clinical Trial Phase
Clinical Trial Sponsors for fruquintinib
Sponsor Name
